{"id":"W4401792490","doi":"10.1093/oncolo/oyae215","title":"Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Foundation Medicine; EMD Serono; Eisai; National Cancer Institute; Aptitude Health; Natera; Seagen; Loxo Oncology; Astellas Pharma; Calithera Biosciences; Mirati Therapeutics; bluebird bio; Sanofi; Exelixis; Genentech; MEI Pharma; Regeneron Pharmaceuticals; Gilead Sciences; Merck KGaA; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Gemcitabine; Pembrolizumab; Avelumab; Carboplatin; Medicine; Chemotherapy; Cisplatin; Oncology; Nivolumab; Metastatic Urothelial Carcinoma; Regimen; Internal medicine; Urothelial carcinoma; Bladder cancer; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005214799,0.0004573363,0.001166504,0.00007730877,0.0001537238,0.00003416085,0.0003737171,0.0001469759,0.00004207897],"category_scores_gemma":[0.00008573876,0.0001494144,0.00041894,0.0003327514,0.0001741234,0.00002301684,0.00002620081,0.0002936936,0.000008118352],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004544508,"about_ca_system_score_gemma":0.001016855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001424594,"about_ca_topic_score_gemma":0.000138508,"domain_scores_codex":[0.9981185,0.0002758651,0.0005253513,0.0003745018,0.0003893602,0.0003164381],"domain_scores_gemma":[0.9977937,0.001010695,0.0003776792,0.0006907561,0.0000940348,0.00003318698],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000921601,0.0006281675,0.002114157,0.002061518,0.0004297732,0.000008549466,0.00111426,0.00001058381,0.000001274959,0.00003715796,0.0002332463,0.9924397],"study_design_scores_gemma":[0.01572411,0.014142,0.002982841,0.009130603,0.009393337,0.00002577329,0.0008551507,0.0004445481,0.00003141222,0.0001960019,0.9466196,0.0004546214],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002200871,0.9851386,0.000007070068,0.0003648256,0.0001461968,0.008419878,0.000282844,0.00003250999,0.003407189],"genre_scores_gemma":[0.140731,0.8485085,0.0007415425,0.0005170124,0.0007719092,0.007559012,0.0004108094,0.000236418,0.0005237584],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9919851,"threshold_uncertainty_score":0.6092942,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04167354747080428,"score_gpt":0.360458438488445,"score_spread":0.3187848910176407,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}